Rencofilstat

Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease[1].

Product Specifications

CAS Number

[1383420-08-3]

Product Name Alternative

CRV431

UNSPSC

12352005

Target

Cyclophilin; Interleukin Related; Nuclear Factor of activated T Cells (NFAT) ; Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rencofilstat.html

Purity

90.29

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O[C@@H]([C@](C(N[C@H](C(N([C@@H](C(N([C@H](C(N[C@H](C(N([C@H]1CC(C)C)C)=O)C(C)C)=O)CC(C)C)C)=O)C)C)=O)CC)=O)([H])N(C([C@@H](N(C([C@@H](N(C([C@@H](N(C([C@H](NC([C@@H](NC1=O)C)=O)C)=O)C)CC(C)C)=O)C)CC(C)C)=O)C)C(C)C)=O)C)[C@H](C)CCCCCCNC(C)=O

Molecular Formula

C67H122N12O13

Molecular Weight

1303.76

References & Citations

[1]Joseph Kuo, et al. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. J Pharmacol Exp Ther. 2019 Nov;371 (2) :231-241.